# Merit 0.5 G

Specimen Label

Merit® 0.5 G

Distributed By

BUTTLER'S MILL, INC. SAN DIEGO, CA

(619) 263-6181 Fax: (619) 262-3659

# Insecticide

For systemic insect control in turfgrass and landscape ornamentals.

**ACTIVE INGREDIENT:** 

 Imidacloprid, 1-[(6-Chloro-3-pyridinyl)methyl]- N-nitro-2-imidazolidinimine
 0.5%

 INERT INGREDIENTS
 99.5%

 100.00%

EPA Reg. No. 3125-451

30-Pound Bag

# STOP - Read The Label Before Use KEEP OUT OF REACH OF CHILDREN

# CAUTION

PRECAUCION AL USUARIO: Si usted no puede leer o entender inglés, no use este producto hasta que la etiqueta le haya sido explicada ampliamente.

(TO THE USER: If you cannot read or understand English, do not use this product until the label has been fully explained to you.)

# PRECAUTIONARY STATEMENTS HAZARDS TO HUMANS AND DOMESTIC ANIMALS

CAUTION: Harmful if swallowed or absorbed through skin. Causes eye irritation. Avoid

contact with skin, eyes, or clothing. Wash thoroughly with soap and water after handling.

### STATEMENTS OF PRACTICAL TREATMENT

If swallowed: Call a physician or Poison Control Center. Drink one or two glasses of water and induce vomiting by touching back of throat with finger, or, if available, by administering syrup of ipecac. If syrup of ipecac is available, administer 1 tablespoonful (15 mL) of syrup of ipecac followed by 1 to 2 glasses of water. If vomiting does not occur within 20 minutes, repeat the dose once. Do not induce

vomiting or give anything by mouth to an unconscious person. If on skin: Wash thoroughly with soap and water. Get medical attention if irritation occurs. If in eyes: Hold eyelids open and flush with plenty of water. Call a physician if irritation persists.

To Physician: No specific antidote is available. Treat the patient symptomatically.

### ENVIRONMENTAL . JAZARDS

This product is highly toxic to aquatic invertebrates. Do not apply directly to water, or to areas where surface water is present or to intertidal areas below the mean high water mark. Do not contaminate water when disposing of equipment washwaters

This chemical demonstrates the properties and characteristics associated with chemicals detected in groundwater. The use of this chemical in areas where soils are permeable, particularly where the water table is shallow, may result in groundwater contamination.

# **DIRECTIONS FOR USE**

It is a violation of Federal law to use this product in a manner inconsistent with its labeling

IMPORTANT: Read these entire DIRECTIONS FOR USE, GENERAL INFORMATION, AND CONDITIONS OF SALE before using MERIT 0.5 G Insecticide.

COMDITIONS OF SALE: THE DIRECTIONS ON THIS LABEL WERE DETERMINED THROUGH RESEARCH TO BE APPROPRIATE FOR THE CORRECT USE OF THIS PRODUCT. THIS PRODUCT HAS BEEN TESTED UNDER DIFFERENT ENVIRONMENTAL CONDITIONS BOTH INDOORS AND OUTDOORS UNDER CONDITIONS SIMILAR TO THOSE THAT ARE ORDINARY AND CUSTOMARY WHERE THE PRODUCT IS TO BE USED. INSUFFICIENT CONTROL OF PESTS OR PLANT INJURY MAY RESULT FROM THE OCCURRENCE OF EXTRAORDINARY OR UNUSUAL CONDITIONS, OR FROM FAILURE TO FOLLOW LABEL DIRECTIONS. IN ADDITION,

FAILURE TO FOLLOW LABEL DIRECTIONS MAY CAUSE INJURY TO ANIMALS, MAN, AND DAMAGE TO THE ENVIRONMENT. BAYER OFFERS, AND THE BUYER ACCEPTS AND USES, THIS PRODUCT SUBJECT TO THE CONDITIONS THAT EXTRAORDINARY OR UNUSUAL ENVIRONMENTAL CONDITIONS, OR FAILURE TO FOLLOW LABEL DIRECTIONS ARE BEYOND THE CONTROL OF BAYER AND ARE, THEREFORE, THE RESPONSIBILITY OF THE BUYER.

Do not formulate this product in other end-use products.

# **GENERAL INFORMATION**

### **APPLICATION TO TURFGRASS**

MERIT 0.5 G Insecticide can be used for the control of soil inhabiting pests of turfgrass, such as Northern & Southern masked chafers, Cyclocephala borealis, C. immaculata, and/or C. lurida; Asiatic garden beetle, Maladera castanea; European chafer, Rhizotrogus majalis, May or June beetles, Phyllophaga spp.; Japanese beetle, Popillia japonica; Oriental beetle, Anomala orientalis, Billbugs, Spherophorus spp.; Annual bluegrass weevil, Hyperodes spp.; Black turfgrass ataenius, Ataenius spretulus; Aphodius spp; and Mole crickets, Scapteriscus spp. MERIT 0.5 G Insecticide can also be used for the suppression of cutworms in turfgrass areas. MERIT 0.5 G Insecticide can be used as directed on turfgrass in sites such as home lawns, business and office complexes, shopping complexes, multi-family residential complexes, golf courses, airports, cemeteries, parks, playgrounds, and athletic fields. MERIT Insecticide can not be used on commercial sod farms.

The active ingredient in MERIT 0.5 G Insecticide has sufficient residual activity so that applications can be made preceding the egg laying activity of the target pests. High levels of control can be achieved when applications are made preceding or during the egg laying period. The need for an application can be based on historical monitoring of the site, previous records or experiences, current season adult trapping or other methods. Optimum control will be achieved when applications are made prior to egg hatch of the target pest, followed by sufficient irrigation or rainfall to move the active ingredient through the thatch. Applications should not be made when turfgrass areas are waterlogged or the soil is saturated with water. Adequate distribution of the active ingredient cannot be achieved when these conditions exist. The treated turf must be in such a condition that the rainfall or irrigation will penetrate vertically in the soil profile. Applications cannot exceed a total of 80 lb (0.4 lb of active ingredient) per acre per year.

# APPLICATION TO ORNAMENTALS

MERIT 0.5 G Insecticide can be used as a broadcast application on ornamentals in commercial and residential landscapes. MERIT 0.5 G is a systemic product and will be translocated upward within the plant system. Optimum control will be achieved when applications are followed by sufficient mechanical incorporation, irrigation or rainfall to move the active ingredient into the soil. Applications should be made prior to anticipated pest infestation to achieve optimum levels of control.

Applications of MERIT 0.5 G Insecticide cannot exceed a total of 80 lb (0.4 lb of active ingredient) per acre per year.

NOTE: Not for use in commercial greenhouses, nurseries, on sod farms or on grass grown for seed. For use on plants intended for aesthetic purposes or climatic modification and being grown in interior plantscapes, ornamental gardens or parks, or on golf courses or lawns and grounds.

### APPLICATION EQUIPMENT

Apply MERIT 0.5 G Insecticide uniformly over the area being treated with normally used granular application equipment. Both drop-type and rotary-type spreaders may be used to apply MERIT 0.5 G Insecticide. Avoid the use of spreaders which would apply the material in narrow, concentrated bands. Calibrate application equipment prior to use according to the manufacturer's directions. Check frequently to be sure equipment is working properly and distributing granules uniformly and accurately.

### Spreader settings for MERIT 0.5 G Insecticide

chart can be used as a guide in establishing an accurate rate of MERIT 0.5 G Insecticide. Application rates will vary dependent upon requipment wear and condition of spreader. Carefully calibrate all the equipment used prior to commercial use of this product.

SPREADER	SPEED (mph)	SETTINGS		00054050	SPEED	SETTINGS	
		60 lb/A	80 lb/A	SPREADER	(mph)	60 lb/A	80 lb/A
Model CB4000	3	3-1/4	3-1/2	PSB Prizelawn CBR-II	3	3-1/4	3-1/2
y Drop	3	9	10	Scott's Proturf R-8A	3	Н	- 1
10' Rotary	3	11	1,2	Scott's Proturf SR-1	3	н	1
Turf Tender 24°	3	16 (27)	19 (29)	Scott's PF-1, PF-2, PF-3, PF-4 Drop	3	4	4-1/2
Turf Tender 42°	3	21 (27)	23 (29)	Scott's SS-1 Drop	3	4	4-1/2
	4.5	3.5		Spyker Model 34	3	3.1	3.2
Model 6000	3	B 1/2	С	Vicon Model PS-203	4.5	13	16




		RECOMMEN	DED APPLICATIONS
CROP	PEST	DOSAGE MERIT 0.5 G	REMARKS
Turigrasses	Larvae of: Annual bluegrass weevil Asiatic garden beetle Billbugs Black turfgrass ataenius Cutworm (suppression) European chafer Japanese beetle Northern masked chafer Orlental beetle Phyllophaga spp. Southern masked chafer	or 1.4 to 1.8 lb per 1000 sq ft	For optimum control of grubs, billbugs and annual bluegrass weevi make application prior to egg hatch of the target pest.  Be sure to read "APPLICATION EQUIPMENT" Section of this label.
	Mole crickets	80 lb per acre or 1.8 lb per 1000 sq ft	For control of mole crickets make application prior to or during the peak egg hatch period. When adults or large nymphs are present and actively tunneling, MERIT application should be accompanied by a curative insecticide.

Consult your local State Agricultural Experiment Station, or State Extension Turf Specialists for more specific information regarding timing of application.

NOTE: For optimum control, irrigation or rainfall should occur within 24 hours after application to move the active ingredient through the thatch. On golf courses, irrigate treated areas following application. Do not apply more than 80 lb (0.4 lb of active ingredient) per acre per year. Avoid mowing turf or lawn area until after irrigation or rainfall has occurred so that uniformity of application will not be affected.

# MATERIAL SAFETY DATA SHEET



BAYER CORPORATION AGRICULTURE DIVISION P.O. Box 4913, Hawthorn Road Kansas City, Missouri 64120-0013 (816) 242-2000

APPROVAL DATE
SUPERSEDES

09/23/94 07/20/94

TRANSPORTATION EMERGENCY NON-TRANSPORTATION BAYER EMERGENCY RESPONSE ..... (800) 414-0244 ...: 800-424-9300 CALL CHEMTREC BAYER CUSTOMER SERVICE ...... (800) 842-8020 DISTRICT OF COLUMBIA ...... 202-483-7616 cause silicosis, a form of disabling, progressive and sometimes latal fibrotic jung PRODUCT IDENTIFICATION PRODUCT NAME..... MERIT 0.5 G Insecticide disease. Severe and permanent lung damage may result. PRODUCT CODE ... CARCINOGENICITY 21654 EPA REGISTRATION NO.... 3125-451 NTP. ....: Crystalline silica is classified as an NTP anticipated human carcinogen - "substances or groups of substances that CHEMICAL FAMILY ..... ...: Chloronicotinyl CHEMICAL NAME..... ....: 1-{(6-chloro-3-pyridinyl)methyl}-N-nitro-2may reasonably be anticipated to be carcinogens." .: "IARC Monographs on the Evaluation imidazolidinimine of the Carcinogenic Risk of Chemicals to Hurnans," Vol. 42 - for crystalline silica SYNONYMS..... .: Imidacloprid; BAY NTN 33893 (quartz) - has concluded that there is "sufficient evidence for the carcinogenicity of FORMULA..... · C9 H10 CLN5 02 crystalline silica to experimental animals" and "limited evidence for the carcinogenicity of crystalline silica to humans." II. HAZARDOUS INGREDIENTS INGREDIENT NAME OSHA. ....: Not regulated. MEDICAL CONDITIONS AGGRAVATED /CAS NUMBER **EXPOSURE LIMITS** CONCENTRATION (%) Imidacloprid BY EXPOSURE ..... ...: No specific medical conditions are 138261-41-3 known which may be aggravated by exposure to the active ingredient in this product: OSHA .....: Not Established 0.5% however, pulmonary and respiratory diseases may be aggravated by exposure to ACGIH .....: Not Established respirable crystalline silica. Total crystalline silics (quartz) VI. EMERGENCY AND FIRST AID PROCEDURES 14808-60-7 FIRST AID FOR EYES ...... Hold eyelids open and flush with copious OSHA .....: .100 mg/m3 TWA (respirable) amounts of water for 15 minutes. Call a physician if irritation persists or develops ACGIH .....: .100 mg/m3 TWA (respirable) after flushing. III. PHYSICAL PROPERTIES FIRST AID FOR SKIN ..... ......: Remove contaminated clothing. Wash skin with soap and water. Get medical attention if irritation persists. If signs of intoxication PHYSICAL FORM : Granules: Solid (poisoning) occur, get medical attention immediately. COLOR ..... .....: Grav ODOR... FIRST AID FOR INHALATION...... First, remove victim to fresh air or ..: None ODOR THRESHOLD ...... uncontaminated area. If not breathing, give artificial respiration, preferably ...: Not established MOLECULAR WEIGHT ..... mouth-to-mouth. Get medical attention as soon as possible. ....: 255.7 (for imidacloprid) FIRST AID FOR INGESTION ...... If ingestion is suspected, call a physician or **BOILING POINT ....** .: Not applicable MELTING/FREEZING POINT .... ..: Melting: 120-134 C (for imidacloprid) poison control center. Drink one or two glasses of water and induce vomiting by VISCOSITY .: Not applicable touching back of throat with finger or if available, by administering syrup of ipecac. SOLUBILITY IN WATER ... If syrup of ipecac is available, administer 1 tablespoonful (15 mL) of syrup of ipecac ...: Granules disperse in water; not soluble followed by 1 to 2 glasses of water. If vomitting does not occur within 20 minutes, repeat SOLUBILITY (NON AQUEOUS)...... Not soluble in common solvents SPECIFIC GRAVITY the dose once. Do not induce vomiting or give anything by mouth to an unconscious ..: Not applicable BULK DENSITY .... : 55-62 lb/cu ft % VOLATILE BY VOLUME..... NOTE TO PHYSICIAN ..... ..: Not applicable .......... Treat symptomatically. In case of VAPOR PRESSURE ....: 1.5 x 10 -9 mm @ 20 C (for imidacloprid) poisoning, it is also requested that Bayer Corporation, Addiculture Division. VAPOR DENSITY ..... Kansas City, Missouri, be notified. Telephone:800/842-8020 (working hours) or ....: Not applicable (Air = 1) 800/414-0244 (non-working hours). IV. FIRE AND EXPLOSION DATA ANTIDOTES .. FLASH POINT... .....: Not applicable VII. EMPLOYEE PROTECTION RECOMMENDATIONS FLAMMABLE LIMITS: UPPER EXPLOSIVE LIMIT (UEL) (%) ..... EYE PROTECTION REQUIREMENTS ...... Goggles should be used when needed ...: Not established LOWER EXPLOSIVE LIMIT (LEL) (%) ..... to prevent granular material or dust from getting into the eyes. ....: Not established EXTINGUISHING MEDIA..... SKIN PROTECTION REQUIREMENTS...... Wear long sleeves and trousers to ..: Water; Carbon Dioxide; Dry Chemical: prevent skin contact. Foam SPECIAL FIRE FIGHTING HAND PROTECTION REQUIREMENTS ...... The use of chemical-resistant gloves to prevent skin contact is recommended as good practice. PROCEDURES ..... ...: Keep out of smoke, cool RESPIRATOR REQUIREMENTS..... exposed containers with water spray. Fight fire from upwind position. Use ..: Under normal handling conditions. no respiratory protection is needed; however, if use conditions generate excessive dust self-contained breathing equipment. Contain runoff by diking to prevent entry into sewers or waterways. Equipment or materials involved in pesticide fires may concentrations, wear a respirator approved for pesticide use by the National Institute become contaminated for Occupational Salety and Health (NIOSH). VENTILATION REQUIREMENTS..... ....: Maintain exposure levels below the V. HUMAN HEALTH DATA applicable exposure limit through the use of general and local exhaust ventilation ROUTE(S) OF ENTRY ... ..: Inhalation; Skin contact; Skin absorption where needed. HUMAN EFFECTS AND SYMPTOMS OF OVEREXPOSURE: ADDITIONAL PROTECTIVE MEASURES..... ACUTE EFFECTS OF EXPOSURE ...... No specific symptoms of acute ..: Clean water should be available for washing in case of eye or skin contamination. Educate and train employees in safe use overexposure are known to occur in humans. Data extrapolated from animal studies performed on a similar product have shown that this material is mildly toxic by the oral of the product. Follow all label instructions. Launder clothing after use. Wash thoroughly after handling. and dermal routes. It is not a dermal irritant or a dermal sensitizer. An acute eye irritation study on this product has shown that this material is mildly irritating to the conjunctiva of the eye, but the irritation is reversible within 7 days. CHRONIC EFFECTS OF EXPOSURE....... No specific symptoms of chronic overexposure to the active ingredient in this material are known to occur in humans DISTRIBUTED BY: This product may contain an amount of total crystalline silica (quartz) which ranges from approximately 2 to 6%. However, the amount of respirable crystalline silica is BUTLER'S MILL, INC. 1619) 263 6181 expected to be significantly lower based on data provided by the raw material

NAN PIEGO, CA

manufacturer. Excessive long-term exposure to respirable crystalline silica may

- 7ax2(6/19) 262-3659

VIII. REACTIVITY DATA This is a stable material STABILITY HAZARDOUS POLYMERIZATION. Will not occur None known INCOMPATIBILITIES Strong exothermal reaction above 200 C INSTABILITY CONDITIONS (for imidadoprid) **DECOMPOSITION PRODUCTS** Proposed: HC1, HCN, CO, NOx (for imidacloprid) IX. SPILL AND LEAK PROCEDURES SPILL OR LEAK PROCEDURES ....: Isolate area and keep unauthorized people away. Do not walk through spilled material. Avoid breathing dusts and skin contact. Avoid generating dust (a fine water spray mist, plastic film cover, or floor sweeping compound may be used if necessary). Use recommended protective equipment while carefully sweeping up spilled material. Place in covered container for reuse or disposal, Scrub contaminated area with soap and water. Rinse with water. Use dry absorbent material such as day granules to absorb and collect wash solution for proper dispos" Contaminated soil may have to be removed and disposed. Do not allow material to enter streams, sewers, or other waterways. WASTE DISPOSAL METHOD ........: Follow container label instructions for disposal of wastes generated during use in compliance with the product label. In other situations, bury in an EPA approved landfill or burn in an incinerator approved for pesticide destruction. Do not reuse container. X. SPECIAL PRECAUTIONS AND STORAGE DATA STORAGE TEMPERATURE None/30 day average not to exceed 100 F (MIN/MAX). SHELF LIFE · Not noted : Not noted SPECIAL SENSITIVITY... HANDLING/STORAGE PRECAUTIONS .. ...: Store in a cool dry area designated specifically for pesticides. Do not store near any material intended for use or consumption by humans or animals. XI. SHIPPING INFORMATION TECHNICAL SHIPPING NAME ... ..: Imidacloorid : Insecticides, NOI - NMFC 102120 FREIGHT CLASS BULK .. : Insecticides, NOI - NMFC 102120 FREIGHT CLASS PACKAGE. PRODUCT LABEL Not noted DOT (HM-181) (DOMESTIC SURFACE) PROPER SHIPPING NAME .. ..: Not hazardous or regulated HAZARD CLASS OR DIVISION .. .: Non-regulated IMO / IMDG CODE (OCEAN) PROPER SHIPPING NAME .... ....: Not hazardous or regulated HAZARD CLASS DIVISION NUMBER ..: Non-regulated ICAO / IATA (AIR) PROPER SHIPPING NAME ... : Not hazardous or regulated HAZARD CLASS **DIVISION NUMBER** ....: Non-regulated XII. ANIMAL TOXICITY DATA Only an acute eye irritation study has been performed on this product as formulated. All other acute toxicity data have been extrapolated from studies performed on a similar product, Provado 2.5% Granular, containing a higher percentage of the active ingredient, imidacloprid. The non-acuse information pertains to the technical-grade active ingredient. **ACUTE TOXICITY** ORAL LDSO ..... ...: Male and Female Rat: >4820 mg/kg DERMAL LDSO INHALATION LC50 .... ..: 4 Hr. Exposure to Dust: Male and Female Rat: >5.09 mg/L (analytical) - 1 Hr. Exposure to Dust (extrapolated from 4 hr. LC50): Male and Female Rat: >20 mg/L (analytical). EYE EFFECTS..... ...: Rabbit: Mild irritation to the conjunctiva was observed with all irritation resolving within 7 days. SKIN EFFECTS SENSITIZATION. ..........: Guinea Pig: Not a dermal sensitizer. SUBCHRONIC TOXICITY..... ....: In a 3 week dermal toxicity study, rabbits were treated with the active ingredient, imidacloprid, at the limit dose level of 1000 mg/kg for 6 hours/day, 5 days/week. There were no local or systemic effects observed at any of the levels tested. The no-observed-effect-level (NOEL) was 1000 mg/kg. In a 4 week inhalation study, rats were exposed to dust concentrations of imidacloprid at 5.5, 30.5 and 191.2 mg/cubic meter for 6 hours/day, 5 days/week. Effects observed at the high concentration included decreased body weight gains, decreased heart and

thymus weights, increased liver weights, and induction of the hepatic mixed-function

oxidases. Histopathological examinations did not reveal any organ damage or local injury to the respiratory tract. The NOEL was 5.5 mg/cubic meter based on induction

of the hepatic mixed-function oxidases

	dietary concentrations of 200, 500 or 1250 ppm. Due to the tack of significant effects,
	the high dose was increased to 2500 ppm at 17 weeks for the remainder of the study.
	Effects observed at the high dose included decreased food consumption, increased
	liver weights and elevated serum chemistries. The NOEL was 500 ppm. In chronic
	studies using rats, imidacloprid was administered for 2 years to rats at dietary
	concentrations of 100, 300, 900 or 1800 ppm. Histopathology examinations revealed
	an increased incidence of mineralization in the colloid of the thyroid follicles at
	concentrations of 300 ppm and greater. At 1800 ppm, there were changes in the
	serum chemistries and a slight increase in the incidence of parafollicular hyperplasia
	seen in the thyroids. Body weight gains were reduced at 900 and 1800 ppm. The
	overall NOEL was 100 ppm.
	CARCINOGENICITY Imidacloprid was investigated for carcinogenicity in
	chronic feeding studies using mice and rats at maximum levels of 2000 and 1800 ppm.
	respectively. There was no evidence of a carcinogenic potential observed in either
	species.
	MUTAGENICITY The imidacloprid mutagenicity studies, taken
	collectively, demonstrate that the active ingredient is not genotoxic or mutagenic.
	DEVELOPMENTAL TOXICITY: In a teratology study using rats, irr ' 'cloprid was
	administered by oral gavage during gestation at doses of 10, 30 or 100 mg/kg.
	At the maternally toxic dose of 100 mg/kg, skeletal examinations of the letuses
	revealed a slight increase in the incidence of wavy ribs. The NOELs for maternal
	and developmental toxicity were 10 and 30 mg/kg, respectively. Teratogenic effects
	were not observed at any of the doses tested. Rabbits were administered imidacloprid
	during gestation at oral doses of 8, 24 or 72 mg/kg. At the maternally toxic dose of
	72 mg/kg, reduced body weights and delayed skeletal ossification were observed in
	the fetuses. The NOELs for maternal and developmental toxicity were 8 and 24 mg/kg
	respectively. Teratogenic effects were not observed at any of the doses tested.
	REPRODUCTION In a reproduction study, imidacloprid was
	administered to rats for 2 generations at dietary concentrations of 100, 250 or
	700 ppm. Offspring at 700 ppm, exhibited reduced mean body weights and body
	weight gains. No other reproductive effects were observed. The maternal and
	reproductive NOELs were 100 and 250 ppm, respectively.
	NEUROTOXICITY In an acute oral neurotoxicity study using rats,
	imidacloprid was administered as a single dose at concentrations of 42, 151 or
	307 mg/kg. Clinical observations and neurotoxicity evaluations were performed over a
	period of 15 days followed by a neurohistopathological examination. Deaths attributed
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study,
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study,
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative
VIII	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS  This product is hazardous under the criteria of the Federal OSHA Hazard Communication Standard 29 CFR 1910.1200.  TSCA STATUS  This product is exempt from TSCA Regulation under FIFRA Section 3 (2) (B) (ii) when used as a pesticide.  CERCLA REPORTABLE  QUANTITY  No components listed.  SARA TITLE III:  SECTION 311/312 HAZARD  CATEGORIES  Immediate Health Hazard  SECTION 313
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in females was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
хін.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
XIII.	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze, in a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS
	to imidacloprid were observed at the high dose within a day of treatment. The NOEL for motor and locomotor activity was 42 mg/kg for males. Females at the low dose exhibited minimal decrease in activity in the figure-eight maze. In a subsequent study, the NOEL for motor and locomotor activity in lemales was 20 mg/kg. The NOEL for neurotoxicity was 307 mg/kg based on the absence of treatment-related microscopic lesions in skeletal muscle or neural tissue. In a 13-week neurotoxicity study, imidacloprid was administered to rats at dietary concentrations of 140, 963 or 3027 ppm. At the mid- and high dose, effects observed included reductions in body weight and feed consumption, and clinical chemistry findings. Neurobehavioral changes were observed only in males at the high dose. There were no correlative micropathologic findings in muscle or neural tissues in any animals at any treatment level. The NOEL for neurotoxicity was 3027 ppm. The overall NOEL was 140 ppm.  FEDERAL REGULATORY INFORMATION  OSHA STATUS

........... Dogs were administered imidadoprid for 1 year at

CHRONIC TOXICITY ......

Product Code: 21654

Bayer's method of hazard communication is comprised of Product Labels and

Material Safety Data Sheets. NFPA ratings are provided by Bayer Corporation

as a customer service.